A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation.
暂无分享,去创建一个
S. Steinberg | H. Parnes | C. Higano | D. Petrylak | O. Sartor | J. Wright | W. Figg | G. Chatta | J. Aragon-Ching | M. Hussain | W. Dahut | J. Gulley | P. Arlen
[1] Vitor Mendes Pereira,et al. In Reply. , 2011, Neurosurgery.
[2] S. Steinberg,et al. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. , 2008, The Journal of urology.
[3] C. Tangen,et al. Use of prostate-specific antigen progression (PSA-P) to predict overall survival (OS) in patients (pts) with metastatic prostate cancer (PC): Data from S9346 and S9916 , 2008 .
[4] B. Trock,et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. , 2008, The Journal of urology.
[5] N. Mottet,et al. The role of intermittent androgen deprivation in prostate cancer , 2007, BJU international.
[6] Thomas J. Smith,et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Alan W Partin,et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.
[8] F. Saad,et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Steinberg,et al. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy. , 2005, The Journal of urology.
[10] B. Eser,et al. Inhibition of angiogenesis: thalidomide or low-molecular-weight heparin? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[12] S. Steinberg,et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Walsh,et al. A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment. , 2001, The Journal of urology.
[14] A. Partin,et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.
[15] A W Partin,et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. , 2001, The Journal of urology.
[16] S. Steinberg,et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] W. Figg,et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. , 1999, Journal of pharmaceutical sciences.
[18] I. Thompson,et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.
[19] B. Chauvet,et al. [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin]. , 1998, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.
[20] R. A. Jones,et al. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. , 1997, British journal of urology.
[21] A. Zietman,et al. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. , 1995, International journal of radiation oncology, biology, physics.
[22] W Blumenfeld,et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.
[23] H. Sasaki,et al. Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study , 1992, The Journal of pathology.